JCAR017 (lisocabtagene maraleucel)(Bristol Myers Squibb)은 Leukemia, Lymphocytic, Chronic, B-Cell 표적 세포·유전자 치료로, Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Small Lymphocytic 영역에서 개발·상용화 중입니다. 작용기전: CAR T-cell patients is largely dependent on institutional experience. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 80.5% (ClinicalTrials.gov NCT03744676). 차별점: Novel Drugs.
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Small Lymphocytic
Recruiting
CAR T-cell therapy in large B-cell lymphoma: insights from a nati
vedotin plus bendamustine and rituximab (Pola-B
Novel Drugs
CAR T-cell patients is largely dependent on institutional experience
Cytokine release syndrome was limited to grade 2, and immune effector cell-associated neurotoxicity syndrome occurre
biomarker that predicts delayed humoral immune recovery, increased infectious events, and treatment-related m
resistance to both classes of drugs, resulting in double refractory disease
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
JCAR017 (lisocabtagene maraleucel)(Bristol Myers Squibb)은 Leukemia, Lymphocytic, Chronic, B-Cell 표적 세포·유전자 치료로, Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Small Lymphocytic 영역에서 개발·상용화 중입니다. 작용기전: CAR T-cell patients is largely dependent on institutional experience. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 80.5% (ClinicalTrials.gov NCT03744676). 차별점: Novel Drugs.
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Small Lymphocytic
Recruiting
CAR T-cell therapy in large B-cell lymphoma: insights from a nati
vedotin plus bendamustine and rituximab (Pola-B
Novel Drugs
CAR T-cell patients is largely dependent on institutional experience
Cytokine release syndrome was limited to grade 2, and immune effector cell-associated neurotoxicity syndrome occurre
biomarker that predicts delayed humoral immune recovery, increased infectious events, and treatment-related m
resistance to both classes of drugs, resulting in double refractory disease
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.